, Tracking Stock Market Picks
Enter Symbol:
Penwest Pharmaceuticals Co. (PPCO) [hlAlert]

down 79.41 %

Penwest Pharmaceuticals Co. (PPCO) rated Buy

Posted on: Friday,  Jul 20, 2007  9:25 AM ET by RBC Capital Mkts

RBC Capital Mkts rated Buy Penwest Pharmaceuticals Co. (NASDAQ: PPCO) on 07/20/2007, when the stock price was $12.58.
Since then, Penwest Pharmaceuticals Co. has lost 79.41% as of 11/03/2010's recent price of $2.59.
If you would have followed this RBC Capital Mkts's recommendation on PPCO, you would have lost 79.41% of your investment in 1202 days.

Penwest Pharmaceuticals Co. (Penwest) is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. The Company is developing A0001, a coenzyme Q analog drug candidate that it licensed from Edison Pharmaceuticals, Inc. (Edison), for inherited mitochondrial respiratory chain diseases. The Company is also applying its drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations, referred to as drug delivery technology collaborations.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/20/2007 9:25 AM Buy
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD up  31.57 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy